leadf
logo-loader
viewKintara Therapeutics

DelMar to collaborate with MD Anderson Cancer Center

The collaboration aims to accelerate the development of DelMar’s VAL-083 in brain cancer.

rsz_shutterstock_79850125.jpg
VAL-083 is a "first-in-class," small-molecule chemotherapeutic.

DelMar Pharmaceuticals (OTCQX:DMPI), a clinical-stage drug development company, entered into a collaboration with the University of Texas MD Anderson Cancer Center.

The aim of the collaboration is to accelerate the clinical development of DelMar's lead anti-cancer candidate, VAL-083, for the treatment of glioblastoma multiforme (GBM), the most common and deadly form of brain cancer, the two parties said in a statement on Wednesday.

As part of the collaboration, MD Anderson will start a new Phase II clinical study with VAL-083 in patients with GBM at first recurrence/progression, prior to Avastin exposure. 

"The progress we continue to make with our research shows that VAL-083 may offer advantages over currently available chemotherapies in a number of tumor types," Jeffrey Bacha, DelMar's CEO said in the statement.

"This collaboration will allow us to leverage world-class clinical and research expertise and a large patient population from MD Anderson as we extend and accelerate our clinical focus to include GBM patients following first recurrence of their disease."

VAL-083 is a "first-in-class," small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated clinical activity against a range of cancers including lung, brain, cervical, ovarian tumors and leukemia both as a single-agent and in combination with other treatments.

DelMar shares have lost 6.1% over the past year to close at $0.920 on Tuesday.

Quick facts: Kintara Therapeutics

Price: 1.71 USD

NASDAQ:KTRA
Market: NASDAQ
Market Cap: $52.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read